Table 1.

Characteristics of 1-y survivors by type of first primary NHL diagnosed from age 20 to 84 y, 17 SEER registry areas, 2000 to 2014

CharacteristicCLL/SLL, % (n = 42 119)DLBCL, % (n = 41 416)FL, % (n = 29 508)MZL, % (n = 14 001)
Age at first primary NHL, y
 <6029.546.447.840.1
 ≥6070.553.652.259.9
 Mean65.959.760.462.5
Mean follow-up time, y4.54.65.24.8
Sex
 Male60.554.949.945.4
 Female39.545.150.154.6
Race
 White/unknown90.184.090.483.9
 African American7.47.74.78.1
 Other2.58.34.98.0
Year of first primary NHL diagnosis
 2000-200434.033.234.630.5
 2005-200936.836.237.737.8
 2010-201429.330.627.731.7
First course of NHL treatment
 CT and RT0.624.47.54.6
 CT, no known RT21.161.849.227.9
 RT, no known CT0.72.09.320.1
 No known CT or RT77.611.834.047.4
Stage at first primary NHL*
 Early71.551.642.551.3
 Advanced28.543.150.232.8
 Unknown5.37.315.9
Primary site (NHL)
 Nodal64.340.0
 Extranodal, gastric4.620.3
 Extranodal, nongastric31.039.7
HIV/AIDS status at NHL diagnosis
 Reported HIV/AIDS0.13.60.50.7
 No known HIV/AIDS99.996.499.599.3
  • CT, chemotherapy; RT, radiotherapy.

  • * Early stage: Ann Arbor stages I and II for DLBCL, FL, and MZL and no known initial treatment of CLL; advanced stage: Ann Arbor stages III and IV for DLBCL, FL, and MZL and any initial treatment of CLL.